Key result
Alcohol septal ablation significantly reduced left ventricular hypertrophy and NT-proBNP levels (from 2174.4 to 1103.4 pg/mL) at 6 months in patients with hypertrophic obstructive cardiomyopathy.
Why the study?
The study sought to assess the effect of alcohol septal ablation on left ventricular wall thickness and mass, left atrial size, and NT-proBNP level in patients with HOCM.
Does alcohol septal ablation improve left ventricular mass, left atrial size, and NT-proBNP levels in patients with hypertrophic obstructive cardiomyopathy?
Observational (n=50)
No
Does alcohol septal ablation improve left ventricular mass, left atrial size, and NT-proBNP levels in patients with hypertrophic obstructive cardiomyopathy?
Absolute Event Rate: 1103.4% vs 2091.1%
p-value: p=<0.001
Successful alcohol septal ablation in HOCM patients reduces left ventricular hypertrophy, left atrial size, and NT-proBNP levels, which may serve as useful markers of procedural efficacy.
May support NT-proBNP and LV mass as ASA efficacy markers in HOCM; extends low-certainty observational data but leaves open need for RCTs.
BACKGROUND: Alcohol septal ablation (ASA) is an alternative to surgical treatment in patients with hypertrophic obstructive cardiomyopathy (HOCM). Through alcohol-induced necrosis, ASA leads to an increase in left ventricular outflow tract (LVOT) diameter and a decrease in LVOT pressure gradient. AIM: We sought to assess the effect of ASA on left ventricular (LV) wall thickness and mass, left atrial (LA) size, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) level. METHODS: The study cohort consisted of 50 patients with HOCM (30 in the ASA group, 20 in the optimal pharmacotherapy group [OPG]). Transthoracic echocardiography (TTE), cardiac magnetic resonance (CMR), and NT-proBNP level analysis were performed at baseline and at six months. RESULTS: All parameters are presented as means. In the ASA group, the maximal LVOT pressure gradient decreased from 122.7 to 54.8 mmHg directly after ASA and to 37.2 mmHg after a further six months (p < 0.0001). The NT-proBNP level decreased from 2174.4 to 1103.4 pg/mL (p < 0.001). On TTE, the interventricular septum (IVS) thickness decreased to from 23.6 to 19.4 mm (p < 0.0001) and the lateral wall (LW) thickness decreased from 15.9 to 14.2 mm (p < 0.007). On CMR, basal IVS thickness decreased from 23.7 to 18.0 mm (p < 0.0001) and the LW thickness decreased from 13.2 to 12.2 mm (p = 0.02). IVS mass reduced from 108.9 to 91.5 g (-16%; p < 0.001). All of the above parameters remained unchanged in the OPG. CONCLUSIONS: Successful ASA reduces LV hypertrophy and improves parameters of the LV overload, resulting in LV wall hy-pertrophy regression, and LA size and NT-proBNP level reduction. The above parameters may be as useful in assessing the efficacy of ASA as the LVOT gradient itself.
No takes yet. Share an insight, caveat, or question.
Dąbrowski et al. (2018) conducted an observational in Hypertrophic obstructive cardiomyopathy (HOCM) (n=50). Alcohol septal ablation vs. Optimal pharmacotherapy was evaluated on NT-proBNP level at 6 months (pg/mL) (p=<0.001). Alcohol septal ablation significantly reduced left ventricular hypertrophy and NT-proBNP levels (from 2174.4 to 1103.4 pg/mL) at 6 months in patients with hypertrophic obstructive cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: